{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Enanta Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"ENTA"},"Address":{"label":"Address","value":"500 ARSENAL STREET, WATERTOWN, Massachusetts, 02472, United States"},"Phone":{"label":"Phone","value":"+1 617 607-0800"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline."},"CompanyUrl":{"label":"Company Url","value":"https://www.enanta.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jay R. Luly","title":"President, Chief Executive Officer & Director"},{"name":"Scott T. Rottinghaus","title":"Chief Medical Officer & Senior Vice President"},{"name":"Yat Sun Or","title":"CSO, Senior Vice President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}